Respiratory News and Research

RSS

MOVENTIG (naloxegol) receives EC approval for treatment of opioid-induced constipation

Nektar Therapeutics reported partner AstraZeneca today announced that MOVENTIG (naloxegol) has been granted Marketing Authorisation by the European Commission for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).

9 Dec 2014

Focus Diagnostics' Simplexa Flu A/B & RSV Direct Kit receive FDA clearance

As the 2014-2015 flu season begins, Focus Diagnostics, the products business of Quest Diagnostics, today announced that its Simplexa Flu A/B & RSV Direct Kit has received FDA clearance for eight additional influenza strains. These strains may pose significant potential health risks and may be circulating this winter.

From Quest Diagnostics 9 Dec 2014

Arthritis drug baricitinib meets primary endpoint in Phase 3 RA-BEACON study

Eli Lilly and Company and Incyte Corporation today announce that the Phase 3 RA-BEACON study of the investigational medicine baricitinib met its primary endpoint of improved ACR20 response compared to placebo after 12 weeks of treatment.

9 Dec 2014

Infant mortality rates for RSV much lower than previously thought

It's a virus that has long been characterized as dangerous and even deadly, but new research shows infant deaths from respiratory syncytial virus (RSV) are actually quite uncommon in the 21st century.

9 Dec 2014

Scientists receive NIH grants to explore sudden unexpected death in epilepsy

Nine groups of scientists will receive funding totaling $5.9 million in 2014 to work together on increasing the understanding of sudden unexpected death in epilepsy (SUDEP), the leading cause of death from epilepsy. The consortium becomes the second Center Without Walls, an initiative to speed the pace of research on difficult problems in epilepsy by promoting collaborative research.

9 Dec 2014

$IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL$

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

New IMBRUVICA (ibrutinib) Phase II data announced by Pharmacyclics, Inc. today demonstrates its potential utility as a combination therapy when used with rituximab. Data suggest that the overall efficacy and safety profile of IMBRUVICA is well tolerated when combined with rituximab in patients with relapsed or refractory mantle cell lymphoma (MCL).

9 Dec 2014

Case Western Reserve selected to lead $27.3 million international effort to identify causes of SUDEP

Case Western Reserve is one of two universities in the country selected to lead a $27.3 million international effort to identify the causes of a mysterious and deadly phenomenon that strikes people with epilepsy without warning.

9 Dec 2014

Experts launch new interdisciplinary scientific collaboration to improve health in urban areas

Aiming to empower planners and policy-makers to achieve better health for billions of people living in fast-growing urban areas, world health, environmental, behavioural and social science experts today launched a major new interdisciplinary scientific collaboration.

9 Dec 2014

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Results from the Phase 2 RESONATE-17 (PCYC-1117) study show IMBRUVICA (ibrutinib) was associated with an 82.6 percent investigator-assessed overall response rate (ORR; the primary endpoint) and a 79 percent progression-free survival (PFS) rate at 12 months in people living with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have a genetic mutation known as deletion 17p (del 17p).

9 Dec 2014

Children born prematurely need to be placed in a priority group for seasonal flu vaccination

Children born prematurely are at an increased risk of flu-related complications, despite not being identified as an “at risk” group in UK, USA, or WHO guidelines, and should be a priority group for the seasonal flu vaccination, new research published in The Lancet Respiratory Medicine suggests.

8 Dec 2014

Vitamin C may reduce exercise-induced bronchoconstriction and respiratory symptoms

Physical activity increases oxidative stress, and therefore, as an antioxidant vitamin C might have particularly evident effects on people who are participating in vigorous exercise. In several studies, vitamin C administration attenuated the increases in oxidative stress markers caused by exercise. Furthermore, vitamin C is involved in the metabolism of histamine, prostaglandins, and cysteinyl leukotrienes, all of which appear to be mediators in the pathogenesis of exercise-induced bronchoconstriction.

8 Dec 2014

Study shows link between cardiac abnormalities, sudden unexpected death in epilepsy

Groundbreaking findings describing the link between cardiac abnormalities and sudden unexpected death in epilepsy (SUDEP) will be presented at the American Epilepsy Society's Annual Meeting in December.

7 Dec 2014

New treatment combinations improve outcomes for vulnerable patient with hard-to-treat disease

New treatment combinations and targeted therapies for lymphoma and multiple myeloma are improving outcomes for vulnerable patient populations with hard-to-treat disease, according to studies presented today at the 56th American Society of Hematology Annual Meeting and Exposition.

7 Dec 2014

Adding maintenance therapy after transplant can improve outcomes in Hodgkin lymphoma patients

In a late-stage clinical trial, Hodgkin lymphoma (HL) patients who received brentuximab vedotin (BV) post-transplant lived longer without disease progression than patients who received only supportive care. This is the first time a study has demonstrated that adding a maintenance therapy after transplant can improve outcomes.

7 Dec 2014

IMBRUVICA demonstrates anti-tumor activity against multiple myeloma in Phase II study

New IMBRUVICA (ibrutinib) Phase II data announced here today by Pharmacyclics, Inc) during the 56th American Society of Hematology Annual Meeting suggests that IMBRUVICA demonstrates anti-tumor activity both as a single-agent and as combination therapy in heavily pre-treated patients with relapsed or relapsed/refractory multiple myeloma (MM).

7 Dec 2014

Orexo announces positive results from ISTART/006 study

Orexo US, Inc. announced results from the ISTART/006 study, being presented today at the 25th Annual Meeting and Symposium of the American Academy of Addiction Psychiatry in Aventura, Florida, USA.

7 Dec 2014

FDA Advisory Committee votes in favor of Actavis' ceftazidime-avibactam

Actavis plc today announced that the Anti-Infective Drugs Advisory Committee convened by the U.S. Food and Drug Administration has voted to recommend approval of Actavis' New Drug Application (NDA) for ceftazidime-avibactam, an investigational antibiotic being developed to treat hospitalized patients when limited or no treatment options are available for complicated intra-abdominal infections (cIAI) (in combination with metronidazole) and complicated urinary tract infections (cUTI) (including acute pyelonephritis) caused by Gram-negative pathogens.

5 Dec 2014

Pharmacyclics launches informCLL registry to explore natural history of CLL patients

Pharmacyclics, Inc. today announced the launch of informCLL, a large, observational, prospective registry that will explore the natural history of chronic lymphocytic leukemia (CLL), examine how IMBRUVICA (ibrutinib) and other approved targeted therapies are being used to treat patients with CLL, and provide a comparison to treatments using conventional chemoimmunotherapy (CIT).

5 Dec 2014

Increasing length of breastfeeding could save over £40 million annually for NHS

The NHS could save more than £40 million a year by increasing the length of time that mothers breastfeed, according to research carried out at Brunel University London.

5 Dec 2014

New study finds link between birth weights and academic performance in school

It's no secret that low-birth-weight babies face significantly greater risks for certain health problems early on, such as respiratory distress or infection. Now, a new study from researchers at the University of Florida and Northwestern University shows that lower weights at birth also have an adverse effect on children's performance in school, which is likely due to the early health struggles small babies often face.

5 Dec 2014

Respiratory News and Research

MOVENTIG (naloxegol) receives EC approval for treatment of opioid-induced constipation

Focus Diagnostics' Simplexa Flu A/B & RSV Direct Kit receive FDA clearance

Arthritis drug baricitinib meets primary endpoint in Phase 3 RA-BEACON study

Infant mortality rates for RSV much lower than previously thought

Scientists receive NIH grants to explore sudden unexpected death in epilepsy

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

Case Western Reserve selected to lead $27.3 million international effort to identify causes of SUDEP

Experts launch new interdisciplinary scientific collaboration to improve health in urban areas

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Children born prematurely need to be placed in a priority group for seasonal flu vaccination

Vitamin C may reduce exercise-induced bronchoconstriction and respiratory symptoms

Study shows link between cardiac abnormalities, sudden unexpected death in epilepsy

New treatment combinations improve outcomes for vulnerable patient with hard-to-treat disease

Adding maintenance therapy after transplant can improve outcomes in Hodgkin lymphoma patients

IMBRUVICA demonstrates anti-tumor activity against multiple myeloma in Phase II study

Orexo announces positive results from ISTART/006 study

FDA Advisory Committee votes in favor of Actavis' ceftazidime-avibactam

Pharmacyclics launches informCLL registry to explore natural history of CLL patients

Increasing length of breastfeeding could save over £40 million annually for NHS

New study finds link between birth weights and academic performance in school

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News